FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma Read more about FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Amgen To Present At The 36th Annual J.P. Morgan Healthcare Conference Read more about Amgen To Present At The 36th Annual J.P. Morgan Healthcare Conference
Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral Read more about Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral
Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend Read more about Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend
KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial Read more about KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires Read more about Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires
New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers Read more about New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers
Amgen To Webcast Investor Call At ASH 2017 Read more about Amgen To Webcast Investor Call At ASH 2017
FDA Approves Amgen's Repatha® (evolocumab) To Prevent Heart Attack And Stroke Read more about FDA Approves Amgen's Repatha® (evolocumab) To Prevent Heart Attack And Stroke
Aimovig™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention Read more about Aimovig™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention
